Physician profile
Amanda Schultz
NPI 1932562097
$3,501.68
in general payments reported to CMS, 2019-2025
18 companies · $891 in 2025
The $891 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $388 · 2022: $281 · 2023: $893 · 2024: $1,049 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $628.58 | 2021-2025 | |
| Boston Scientific Corporation | $482.84 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, General - Pain Management, Watchman Flx |
| Amgen INC. | $381.82 | 2023-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $332.39 | 2021-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $332.24 | 2023-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $228.50 | 2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $187.57 | 2022-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $184.74 | 2023-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $175.45 | 2022-2025 | Camzyos |
| Pfizer INC. | $148.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.77 | 2021-2022 | |
| Abbott Laboratories | $85.79 | 2022-2025 | Aveir, Gallant |
| Novo Nordisk INC | $51.37 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $45.83 | 2025 | Attruby |
| Lilly USA, LLC | $30.71 | 2025 | Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $24.32 | 2022 | |
| Esperion Therapeutics, INC. | $19.97 | 2024 | Nexletol |
| Resmed Corp | $16.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.